These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 23402735)

  • 1. Anti-atherosclerotic mechanisms of statin therapy.
    Babelova A; Sedding DG; Brandes RP
    Curr Opin Pharmacol; 2013 Apr; 13(2):260-4. PubMed ID: 23402735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin therapy-evidence beyond lipid lowering contributing to plaque stability.
    de Lorenzo F; Feher M; Martin J; Collot-Teixeira S; Dotsenko O; McGregor JL
    Curr Med Chem; 2006; 13(28):3385-93. PubMed ID: 17168712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering].
    Fujita R; Matsushima T
    Nihon Rinsho; 1999 Dec; 57(12):2821-5. PubMed ID: 10638219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy.
    Zhou Q; Liao JK
    Curr Pharm Des; 2009; 15(5):467-78. PubMed ID: 19199975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleiotropic effects of HMG-CoA reductase inhibitors.
    Werner N; Nickenig G; Laufs U
    Basic Res Cardiol; 2002 Mar; 97(2):105-16. PubMed ID: 12002257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of statin therapy on the progression of chronic kidney disease.
    Shah S; Paparello J; Danesh FR
    Adv Chronic Kidney Dis; 2005 Apr; 12(2):187-95. PubMed ID: 15822054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleiotropic effects of statins--clinical evidence.
    Athyros VG; Kakafika AI; Tziomalos K; Karagiannis A; Mikhailidis DP
    Curr Pharm Des; 2009; 15(5):479-89. PubMed ID: 19199976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?
    Balakumar P; Mahadevan N
    Br J Pharmacol; 2012 Jan; 165(2):373-9. PubMed ID: 21790534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The pleiotropic effects of statins].
    Wolfovitz E
    Harefuah; 2005 Aug; 144(8):577-82, 597. PubMed ID: 16146158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro study over statins effects on cellular growth curves and its reversibility with mevalonate].
    Millan Núñez-Cortés J; Alvarez Rodriguez Y; Alvarez Novés G; Recarte Garcia-Andrade C; Alvarez-Sala Walther L
    Clin Investig Arterioscler; 2014; 26(1):1-9. PubMed ID: 24126321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-atherosclerotic actions of HMG-CoA reductase inhibitors].
    Gmiński J; Wojakowski W
    Przegl Lek; 1997; 54(11):782-7. PubMed ID: 9501689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antiplatelet and antithrombotic actions of statins.
    Mitsios JV; Papathanasiou AI; Goudevenos JA; Tselepis AD
    Curr Pharm Des; 2010; 16(34):3808-14. PubMed ID: 21128896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials].
    Wojakowski W; Gmiński J
    Przegl Lek; 2000; 57(5):291-5. PubMed ID: 11057120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Statins: possibly more than just lowering of the lipid level].
    Visseren FL; Lansberg PJ; Erkelens DW; Kastelein JJ
    Ned Tijdschr Geneeskd; 2000 Feb; 144(7):316-21. PubMed ID: 10707742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.
    Sadowitz B; Maier KG; Gahtan V
    Vasc Endovascular Surg; 2010 May; 44(4):241-51. PubMed ID: 20403949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.
    Ito MK; Talbert RL; Tsimikas S
    Pharmacotherapy; 2006 Jul; 26(7 Pt 2):85S-97S; discussion 98S-101S; quiz 106S-108S. PubMed ID: 16803418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of statins in clinical medicine--LDL--cholesterol lowering and beyond.
    Rutishauser J
    Swiss Med Wkly; 2006 Jan; 136(3-4):41-9. PubMed ID: 16633945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological effects of HMG-CoA reductase inhibitors].
    Tomita N; Morishita R; Ogihara T
    Nihon Rinsho; 2002 May; 60(5):955-61. PubMed ID: 12029999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.